MMRP DEMO LOSS PMS2 case

Immunotherapy Available for Tumors Identified as dMMR or MSI-H

MMRP DEMO LOSS PMS2 case

Patients with unresectable or metastatic solid tumors identified as mismatch repair deficient (dMMR by IHC) or microsatellite instability-high (MSI-H by PCR) who have progressed following other treatments are now eligible for Keytruda® (pembrolizumab) immunotherapy. A recent FDA accelerated approval based on these biomarkers permits the use of Keytruda®  immunotherapy in qualified patients, regardless of solid tumor site.

For additional information on these biomarker assays, visit CSI’s
MMR and MSI Testing Page